Wegovy Doesn’t Work for Everyone: Woman’s Frustration Highlights Non-Response Rates
The GLP-1 Weight Loss Drug Hype: Why It Doesn’t Work for Everyone
The buzz around GLP-1 drugs like Ozempic and Mounjaro is deafening, with many hailing them as miracle weight-loss solutions. but for some patients, the reality is far less glamorous.
While these medications have shown notable results for many, a significant number of individuals experience little to no weight loss, leaving them feeling frustrated and discouraged.
Danielle Griffin,a 38-year-old woman,knows this feeling all too well. Despite securing a prescription for Novo Nordisk’s Wegovy and overcoming the hurdle of insurance coverage, Griffin’s experience with the drug has been underwhelming.
“I have been on Wegovy for a year and a half,” Griffin shared, “and have only lost 13 pounds.”
Griffin diligently followed her doctor’s recommendations,incorporating diet,exercise,and hydration into her routine. Yet, the scale barely budged.
“It’s discouraging,” she admitted.
While much attention has been focused on the potential side effects of GLP-1 drugs,which mimic the body’s feeling of fullness,the issue of non-responsiveness has received less scrutiny.
Experts, however, estimate that up to 20% of patients may not experience weight loss with these medications.
Dr. Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital, explains that individual responses to GLP-1s can vary widely.
“Different people have different responses,” Dr. Stanford said. “These drugs won’t work the same for everyone who takes them.”
Factors such as underlying medical conditions, brain and gut chemistry, and even the specific type of GLP-1 drug can influence how effectively a person metabolizes the medication.”Obesity is a disease that stems from the brain,” Dr. Stanford emphasized. “The dysfunction may not be the same.”
Endocrine specialist Jody Dushay of Boston’s Beth Israel deaconess Medical Center has also observed cases of non-responsiveness to GLP-1s.
“Generally, we can tell within a few weeks whether the medication is going to work,” dr. Dushay noted.
For those who don’t see results or experience undesirable side effects like nausea and vomiting,the journey can feel disheartening.
However,Dr. Dushay reassures patients that it’s not the end of the road.
“I tell them: it’s not game over,” she said.
Switching to a different GLP-1 drug, as Griffin did with zepbound, can sometimes yield better results.
Griffin, after three months on Zepbound, has already lost seven pounds and remains hopeful for continued progress.
“I’m hoping it’s slow and steady,” she said.
The GLP-1 drug landscape is complex, and while these medications offer hope for many, it’s crucial to remember that they are not a one-size-fits-all solution. Open interaction with healthcare providers and a willingness to explore option options are key to finding the most effective weight management strategy.
The GLP-1 Weight loss Drug Hype: Why It Doesn’t Work for Everyone
The buzz around GLP-1 drugs like Ozempic and Mounjaro is deafening, with many hailing them as miracle weight-loss solutions. But for some patients,the reality is far less glamorous.
While these medications have shown notable results for many, a significant number of individuals experience little to no weight loss, leaving them feeling frustrated and discouraged.
Danielle Griffin, a 38-year-old woman, knows this feeling all too well.Despite securing a prescription for Novo Nordisk’s Wegovy and overcoming the hurdle of insurance coverage, Griffin’s experience with the drug has been underwhelming.
“I have been on Wegovy for a year and a half,” Griffin shared, “and have only lost 13 pounds.”
Griffin diligently followed her doctor’s recommendations, incorporating diet, exercise, and hydration into her routine. Yet, the scale barely budged.
“It’s discouraging,” she admitted.
While much attention has been focused on the potential side effects of GLP-1 drugs, which mimic the body’s feeling of fullness, the issue of non-responsiveness has received less scrutiny.
Experts, however, estimate that up to 20% of patients may not experience weight loss with these medications.
Dr. Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital, explains that individual responses to GLP-1s can vary widely.
“Different people have different responses,” Dr. Stanford said. “These drugs won’t work the same for everyone who takes them.”
Factors such as underlying medical conditions, brain and gut chemistry, and even the specific type of GLP-1 drug can influence how effectively a person metabolizes the medication.
“Obesity is a disease that stems from the brain,” Dr. Stanford emphasized.”The dysfunction may not be the same.”
Endocrine specialist Jody Dushay of Boston’s Beth Israel Deaconess Medical Center has also observed cases of non-responsiveness to GLP-1s.
“Generally, we can tell within a few weeks whether the medication is going to work,” Dr. Dushay noted.
For those who don’t see results or experience undesirable side effects like nausea and vomiting, the journey can feel disheartening.
Though, Dr.Dushay reassures patients that it’s not the end of the road.
“I tell them: it’s not game over,” she said.
Switching to a different GLP-1 drug, as Griffin did with Zepbound, can sometimes yield better results.
Griffin, after three months on Zepbound, has already lost seven pounds and remains hopeful for continued progress.
“I’m hoping it’s slow and steady,” she said.
The GLP-1 drug landscape is complex, and while these medications offer hope for many, it’s crucial to remember that they are not a one-size-fits-all solution. Open interaction with healthcare providers and a willingness to explore options are key to finding the most effective weight management strategy.